The use of dupilumab (Dupixent) for the treatment of atopic dermatitis was associated with an increased risk of psoriasis ...

A new study published in the Journal of American Medical Association showed that dupilumab (Dupixent), used for treating ...

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...

Zai Lab Limited (NASDAQ:ZLAB) is one of the 10 biotech stocks screaming a buy. On June 17, the company delivered positive ...

Investing.com -- Nektar Therapeutics (NASDAQ: NKTR) stock surged 20% following the company’s announcement that it will present top-line data from its REZOLVE-AD Phase 2b clinical trial for atopic ...

Shares of Nektar Therapeutics soared after the company said it would release topline data from a study of its atopic dermatitis treatment rezpegaldesleukin. The stock was up 31% at $12.49 in Monday's ...

Incyte (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the ...

Nektar Therapeutics said it would release topline data from a study of its atopic dermatitis treatment rezpegaldesleukin on Tuesday. Shares climbed 27% to $12.15 in after-hours trading Monday.

Three months after the US Sofdra launch, prescriptions have exceeded Botanix Pharmaceuticals' expectations. What are they ...

The FDA pushed back the Prescription Drug User Fee Act action date for ruxolitinib cream (Opzelura) by three months to September 19, 2025. The extension will allow regulators time to review additional ...